FDA launches AE platform
The FDA has rolled out a new adverse‑event reporting platform as part of recent agency updates, and commentators noted associated leadership changes at CBER alongside draft‑guidance responses. The platform is being positioned as part of a broader effort to modernize how the agency receives and handles individual case safety reports and related PV submissions. (x.com)
The Food and Drug Administration just replaced a patchwork of seven adverse-event databases with one system called the Adverse Event Monitoring System, and the agency says it handles about 6 million reports a year across products from drugs to cosmetics. The launch was announced on March 11, 2026, with a public dashboard that the agency says will move toward real-time publication instead of quarterly releases. (fda.gov) An adverse event report is the paperwork that gets filed when a patient, doctor, or manufacturer says something bad happened after a product was used. The Food and Drug Administration says those reports can reveal patterns and clusters, but a report alone does not prove the product caused the problem. (fda.gov 1) (fda.gov 2) Until now, those reports lived in separate systems that the agency itself called outdated, fragmented, and hard to search. The Food and Drug Administration says those legacy systems cost about $37 million a year to run and created blind spots in postmarket surveillance. (fda.gov) The new system is supposed to work like one front desk instead of seven different inboxes. The Food and Drug Administration says the Adverse Event Monitoring System will consolidate reports across drugs, biologics, vaccines, devices, tobacco, food, cosmetics, and veterinary medicine into one platform. (fda.gov) This is not just a prettier search page. The Food and Drug Administration says the system also includes standardized reporting rules, automated case-processing workflows, artificial-intelligence redaction tools, digitization tools, and analytics meant to spot trends across product categories. (fda.gov) A lot of the plumbing for this was laid before the launch. On January 16, 2024, the Food and Drug Administration began accepting electronic safety reports for human drugs and many biologics in the International Council for Harmonisation E2B(R3) format, which is the structured data standard companies use to send individual case safety reports machine-to-machine. (fda.gov) That standard matters because a safety report is easier to combine, sort, and compare when every company sends the same fields in the same order. The Food and Drug Administration gave submitters until April 1, 2026, to move postmarketing and many premarketing safety reports onto the E2B(R3) format. (fda.gov 1) (fda.gov 2) The agency says the new dashboard will hold real-time adverse-event reports for all Food and Drug Administration-regulated products by the end of May 2026, while historical data gets migrated and old systems get shut down. The same modernization plan also includes application programming interfaces, which are the software connections outside users need if they want computers to pull the data directly. (fda.gov) The politics around the launch come from who oversees biologics, which include vaccines, blood products, and many gene and cell therapies. The Center for Biologics Evaluation and Research is the Food and Drug Administration unit that regulates those products, and the agency’s February 9, 2026 leadership chart lists Vinay Prasad as both Center director and chief medical and scientific officer. (fda.gov 1) (fda.gov 2) That is why industry watchers linked the platform launch to leadership churn and draft-guidance fights at the same center. In practice, the launch gives the Food and Drug Administration a new safety-data backbone just as biologics policy is being argued in public, and the agency says it expects about $120 million in savings over five years from retiring the old systems. (fda.gov)
